YEAST CELLS EXPRESSING AMYLOID BETA AND USES THEREFOR
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer'"'"'s disease.
-
Citations
95 Claims
-
1. -29. (canceled)
- 30. A method of modulating amyloid beta-mediated toxicity, the method comprising contacting a cell expressing a toxicity-inducing amount or form of amyloid beta with an effective amount of a compound that modulates expression or activity of SPO7, KAR9, POG1, KEM1, XRN1, ROM1, NET1, MID2, BOP3, PMT2, POMT2, PSK1, PASK, YBL061C, SEL1L2, PET111, SLS1, SVL3, IVY1, MVP1, SNX8, PBS2, MAP2K4, PKC1, PKN2, WHI5, SLF1, LARP1, YBL086C, YAP1802, PICALM, YPL014W, RTS1, PPP2R5C, SPT21, FMP48, MARK4, PPR1, TEC1, TEAD2, ADE12, ADSSL1, CRM1, XPO1, NAB3, SLAT, SH3KBP1, RTG3, MITF, SRO9, LARP1B, MBP1, DAPK1, MUM2, INP52, SYNJ1, FCY21, GRR1, FBXL2, VPS9, RABGEF1, or OPY1.
-
34. -47. (canceled)
-
48. A method of identifying a compound that inhibits or increases expression or activity of a protein, the method comprising:
- providing a cell expressing PICALM, PPP2R5C, ADSSL1, XPO1, SH3KBP1, SYNJ1, FBXL2, RABGEF1, MARK4, TEAD2, MITF, DAPK1, LARP1, LARP1B, XRN1, POMT2, SNX8, MAP2K4, PASK, NET1, SEL1L2, or PKN2 protein;
contacting the cell with an agent; and
measuring the expression or activity of the protein in the presence of the agent, wherein a reduction or increase in the expression or activity of the protein in the presence of the agent as compared to the expression or activity of the protein in the absence of the agent identifies the agent as a compound that inhibits or increases, respectively, the expression or activity of the protein. - View Dependent Claims (49, 50, 66, 67)
- providing a cell expressing PICALM, PPP2R5C, ADSSL1, XPO1, SH3KBP1, SYNJ1, FBXL2, RABGEF1, MARK4, TEAD2, MITF, DAPK1, LARP1, LARP1B, XRN1, POMT2, SNX8, MAP2K4, PASK, NET1, SEL1L2, or PKN2 protein;
-
51. -56. (canceled)
-
57. A method of identifying a compound that inhibits amyloid beta-mediated toxicity, the method comprising:
- (a) providing a cell expressing an amount or form of amyloid beta that reduces viability of the cell;
(b) contacting the cell with an agent that modulates expression or activity of SPO7, KAR9, POG1, KEM1, XRN1, ROM1, NET1, MID2, BOP3, PMT2, POMT2, PSK1, PASK, YBL061C, SEL1L2, PET111, SLS1, SVL3, IVY1, MVP1, SNX8, PBS2, MAP2K4, PKC1, PKN2, WHI5, SLF1, LARP1, YBL086C, YAP1802, PICALM, YPL014W, RTS1, PPP2R5C, SPT21, FMP48, MARK4, PPR1, TEC1, TEAD2, ADE12, ADSSL1, CRM1, XPO1, NABS, SLA1, SH3KBP1, RTG3, MITF, SRO9, LARP1B, MBP1, DAPK1, MUM2, INP52, SYNJ1, FCY21, GRR1, FBXL2, VPS9, RABGEF1, or OPY1; and
(c) measuring cell viability in the presence of the agent, wherein an increase in cell viability in the presence of the agent as compared to cell viability in the absence of the agent identifies the agent as a compound that inhibits alpha synuclein-mediated toxicity. - View Dependent Claims (58, 59, 60)
- (a) providing a cell expressing an amount or form of amyloid beta that reduces viability of the cell;
-
61. -65. (canceled)
-
68. -84. (canceled)
-
85. A cell comprising:
- (a) a first heterologous nucleic acid encoding a toxicity-inducing form of amyloid beta; and
(b) a second heterologous nucleic acid encoding SPO7, KAR9, POG1, KEM1, XRN1, ROM1, NET1, MID2, BOPS, PMT2, POMT2, PSK1, PASK, YBL061C, SEL1L2, PET111, SLS1, SVL3, IVY1, MVP1, SNX8, PBS2, MAP2K4, PKC1, PKN2, WHI5, SLF1, LARP1, YBL086C, YAP1802, PICALM, YPL014W, RTS1, PPP2R5C, SPT21, FMP48, MARK4, PPR1, TEC1, TEAD2, ADE12, ADSSL1, CRM1, XPO1, NAB3, SLA1, SH3KBP1, RTG3, MITF, SRO9, LARP1B, MBP1, DAPK1, MUM2, INP52, SYNE, FCY21, GRR1, FBXL2, VPS9, RABGEF1, or OPY1. - View Dependent Claims (86, 88, 89, 93, 94, 95)
- (a) a first heterologous nucleic acid encoding a toxicity-inducing form of amyloid beta; and
-
87. (canceled)
-
90. -92. (canceled)
Specification